- Home
- OVID
as 07-26-2024 4:00pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Upcoming Earnings Alert:
Get ready for potential market movements as Ovid Therapeutics Inc. OVID prepares to release earnings report on 02 Aug 2024.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 71.7M | IPO Year: | 2017 |
| Target Price: | $4.04 | AVG Volume (30 days): | 652.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $4.14 | Next Earning Date: | 08-02-2024 |
| Revenue: | $473,535 | Revenue Growth: | 283.80% |
| Revenue Growth (this year): | 495.36% | Revenue Growth (next year): | 2446.61% |
Stock Insider Trading Activity of Ovid Therapeutics Inc. (OVID)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LEVIN JEREMY M | OVID | CEO | Mar 18 '24 | Buy | $2.76 | 18,248 | $50,364.48 | 3,616,715 | SEC Form 4 |
Latest Ovid Therapeutics Inc. News
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Insider Monkey
11 days ago
Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds?
GlobeNewswire
17 days ago
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
MT Newswires
18 days ago
Immunic Names Jason Tardio as COO, Werner Gladdines as Chief Development Officer
GlobeNewswire
a month ago
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Zacks
a month ago
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Zacks
a month ago
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
The Fly
a month ago
Apple downgraded, Kroger upgraded: Wall Street's top analyst calls
Compare OVID vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.